Published in final edited form as:

J Acquir Immune Defic Syndr. 2012 April 15; 59(5): 455–462. doi:10.1097/QAI.0b013e3182410503.

Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267

Kelly E Dooley, MD, PhD¹, Jeong-Gun Park, PhD², Susan Swindells, MBBS³, Reena Allen, MA⁴, David W. Haas, MD⁷, Yoninah Cramer, MS², Francesca Aweeka, PharmD⁵, Ilene Wiggins, RN¹, Amita Gupta, MD¹, Patricia Lizak, BS⁵, Sonia Qasba, MD, MPH⁶, Rolf van Heeswijk, PharmD, PhD, Charles Flexner, MD¹, and the ACTG 5267 Study Team

¹Johns Hopkins University School of Medicine, Baltimore, MD

²Harvard School of Public Health, Boston, MA

³University of Nebraska Medical Center, Omaha, NE

⁴ACTG Operations Center, Silver Spring, MD

⁵Vanderbilt University School of Medicine, Nashville, TN

⁶University of California, San Francisco, CA

⁷Division of AIDS, National Institutes of Health, Bethesda, MD

⁸Tibotec, BVBA, Mechelen, Belgium

Abstract

Background—Drug-drug interactions complicate management of co-infection with HIV-1 and *Mycobacterium tuberculosis*. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral drug efavirenz.

Methods—This was a Phase I pharmacokinetic drug interaction trial. Each healthy volunteer received two 400 mg doses of bedaquiline, the first alone, and the second with concomitant steady-state efavirenz. Plasma pharmacokinetic sampling for bedaquiline and its N-monodesmethyl metabolite (M2) was performed over 14 days after each bedaquiline dose. Steady-state efavirenz pharmacokinetics were also determined. Efavirenz metabolizer status was based on *CYP2B6* composite 516/983 genotype.

Results—Thirty-three of 37 enrolled subjects completed the study. Geometric mean ratios (GMR) for bedaquiline with efavirenz versus bedaquiline alone were 0.82 (90% CI 0.75 to 0.89) for the 14-day area under the concentration-time curve (AUC_{0-336h}) and 1.00 (90% CI 0.88 to 1.13) for the maximum concentration (C_{max}). For M2, the GMR was 1.07 (90% CI 0.97 to 1.19) for AUC_{0-336h} and 1.89 (90% CI 1.66 to 2.15) for C_{max}. There were no Grade 3 or 4 clinical adverse events. One subject developed asymptomatic Grade 3 serum transaminase elevation, prompting study drug discontinuation. Efavirenz concentrations stratified by *CYP2B6* genotype were similar to historical data.

Correspondence, Proofs, and Reprint Requests: Kelly Dooley, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 527, Baltimore, MD 21287, USA. kdooley1@jhmi.edu, tel: (443) 287-0517, fax: (410) 614-9978.

No other conflicts of interest exist

Conclusions—Single-dose bedaquiline was well-tolerated alone and with steady-state efavirenz. The effect of efavirenz on bedaquiline concentrations is unlikely to be clinically significant.

Keywords

tuberculosis; HIV; pharmacokinetics; TMC207; bedaquiline; efavirenz; CYP3A

INTRODUCTION

Of the 9.4 million patients with incident tuberculosis (TB) annually, 1.4 million are co-infected with HIV-1, and globally, TB is the leading cause of death among HIV-infected individuals worldwide.¹ Recent studies have demonstrated that survival among co-infected individuals is improved by initiating antiretroviral therapy (ART) early during TB treatment rather than waiting to complete TB treatment. Such ART is particularly beneficial in co-infected individuals with lower CD4 counts.^{2–5} Concomitant treatment for HIV and TB is, thus, common and is becoming the standard of care in many settings. However, concurrent treatment of TB and HIV is complicated by drug-drug interactions and overlapping drug toxicities.⁶ There is an urgent need for new anti-TB medications that can be given safely with antiretrovirals (ARVs).

The novel diarylquinoline bedaquiline (formerly TMC207) is active against both drug-sensitive and drug-resistant TB and has the potential to shorten treatment duration.^{7, 8} Bedaquiline inhibits the proton pump of *Mycobacterium tuberculosis*, ATP synthase, a novel mechanism of action.^{7, 9} Bedaquiline has demonstrated bactericidal and sterilizing activity in mouse models, and it is synergistic with first-line and second-line TB drugs as well as TB compounds in development.^{10–13} In a phase 2 placebo-controlled trial among patients with multidrug-resistant (MDR) TB, 48% of those randomized to receive bedaquiline together with a 5-drug MDR regimen became sputum culture negative by 8 weeks of treatment compared to 9% who received just the 5-drug MDR regimen.¹⁴ By six months, 79% of patients who received bedaquiline plus standard MDR treatment became culture negative compared with 58% who received standard MDR treatment.¹⁵ Clinical trials are ongoing to identify optimal bedaquiline-containing regimens for drug-sensitive TB and MDR-TB.

Bedaquiline is largely metabolized by cytochrome P450 (CYP) 3A to a less-active N-monodesmethyl metabolite (M2). Bedaquiline undergoes triphasic elimination, and while the average half-life over a dosing interval is about 24 hours, its terminal half-life is approximately 5 months.^{7, 16, 17} Administration with food increases bioavailability by about 95%. Efavirenz, one of the most widely prescribed ARV globally, may induce CYP3A, raising the possibility that efavirenz might adversely lower bedaquiline concentrations. In addition, efavirenz is metabolized primarily by CYP2B6, and genetic variants in *CYP2B6* confer marked interindividual variability in efavirenz pharmacokinetics.^{18, 19}

We conducted a phase I, open-label clinical trial in healthy volunteers to evaluate the effects of efavirenz on the pharmacokinetics of bedaquiline and its M2 metabolite, and to describe the safety and tolerability of single doses of bedaquiline coadministered with steady-state efavirenz. We also compared the pharmacokinetics of efavirenz in this study to historical control values, taking into account *CYP2B6* genotype.

METHODS

Study population

Healthy adults 18–65 years of age were recruited at 5 NIH-funded AIDS Clinical Trials Group (ACTG) sites in the United States. Eligible subjects had negative HIV antibody tests

and normal serum aspartate aminotransferase, alanine aminotransferase, amylase, and lipase values. Subjects were excluded for hemoglobin ≤ 12.0 g/dL (men) or ≤ 11.0 g/dL (women), white blood cell count $< 4,000$ cells/mm³, platelets $< 100,000$ cells/mm³, electrocardiogram (ECG) with QTc > 440 or PR > 200 milliseconds, or clinical evidence of active TB. Other exclusion criteria included breastfeeding, active illicit drug use or dependence, recent use of drugs that inhibit or induce CYP3A, chronic illness, and current use of prescription medications. Women of reproductive potential were excluded because there have been no adequate and well-controlled studies in pregnant women. The study was approved by the institutional review boards of participating sites, and all subjects provided written informed consent. The trial was registered at clinicaltrials.gov (NCT00992069).

Experimental protocol

Study design—This was a two-period, sequential-design pharmacokinetic study (Figure 1). Subjects received a single 400 mg oral dose of bedaquiline on study day 1. Plasma samples for bedaquiline and M2 pharmacokinetic analysis were collected predose, then at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 216, 264, and 336 hours post-dose (days 1–14, pharmacokinetic period 1). On study days 15–28, subjects received efavirenz 600 mg orally once nightly. Plasma samples for steady-state efavirenz pharmacokinetic analysis were collected predose, then at 1, 2, 3, 4, 8, 12, and 24 hours post-dose on day 28. On day 29, a second 400 mg dose of bedaquiline was administered. Pharmacokinetic sampling was performed for bedaquiline and M2, again over 336 hours (days 29–43, PK period 2). Efavirenz 600 mg once nightly was continued throughout the bedaquiline/M2 sampling period. Bedaquiline was given following a standard breakfast (670 kcal, 33% fat), and efavirenz was taken on an empty stomach.

Safety monitoring—Subjects underwent safety evaluations approximately once-weekly during the study. ECG evaluations were performed at baseline and 4–6 hours after each bedaquiline dose. Signs and symptoms, laboratory events, and ECG events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0 (December 2004, August 2009 clarification).²⁰

Drug concentration analysis

Plasma assay for bedaquiline and its M2 metabolite—Bedaquiline and its M2 metabolite were quantified using a reversed phase high-performance liquid chromatographic (HPLC) method with tandem mass spectrometric detection. Bedaquiline and its M2 metabolite and the assay internal standard, halofantrine, were isolated from plasma by a simple acetonitrile precipitation of plasma proteins followed by centrifugation. The clear supernatants were then directly injected onto an ACE-5 C18-AR reverse phase column and eluted with a linear gradient of ammonium formate buffer and acetonitrile containing 0.1% formic acid as the mobile phase. The ion pairs 555.7/58.0 for bedaquiline, 539.8/481.5 for its M2 metabolite and 500/482 for the internal standard were selected for tandem MS detection in MRM mode. The method was linear over the range from 10 – 2500 ng/mL for bedaquiline and M2 ($R = 0.9986$). For measurements of bedaquiline, the inter-assay precision (% coefficient of variation, CV) and deviation (% relative error, RE) were, respectively, 4.3 to 6.1% and –6.2 to 2.4%. The intra-assay CV and RE were, respectively, 2.4 to 10.5% and –9.3 to 8%. For measurements of M2, the inter-assay CV and RE were, respectively, 4.7 to 6.3% and –1.8 to 8.2%, and the intra-assay CV and RE were, respectively, 2.4 to 10.5% and –9.3 to 8.0%. The lower limit of quantification (LLQ) was 10 ng/mL for both bedaquiline and M2.

Plasma assay for efavirenz—Efavirenz was quantified using an isocratic reverse phase HPLC method with ultraviolet (UV) detection. Efavirenz and the internal standard reserpine

were extracted from plasma by acetonitrile protein precipitation followed by centrifugation.²¹ The organic supernatant was then evaporated to dryness under nitrogen and reconstituted with mobile phase. The reconstituted efavirenz and internal standard were injected onto a Waters Symmetry Shield-C8 reverse phase column and eluted with an isocratic mobile phase of sodium phosphate and acetonitrile. Detection was performed using a photodiode-array detector, scanning at a wavelength of 247 nm. The method was linear over the range from 100 – 10,000 ng/mL for efavirenz concentrations ($R = 0.9995$). For measurements of efavirenz, the inter-assay CV and RE were, respectively, 2.4 to 4.5% and –0.4 to 3.3% and the intra-assay CV and RE were, respectively, 0.6 to 3.0% and –0.4 to 0.8%. The LLQ was 100 ng/mL.

CYP2B6 metabolizer status—Genomic DNA was extracted from whole blood. Genotyping of known functional polymorphisms *CYP2B6* 516G→T (rs3745274, *CYP2B6**6) and 983T→C (rs28399499, *CYP2B6**18), and of infrequent variants with uncertain effects including rs35303484 (*CYP2B6**11), rs35773040 (*CYP2B6**14), rs2279343 without rs3745274 (*CYP2B6**4), rs35979566 (*CYP2B6**15), and rs3211371 (*CYP2B6**5) was accomplished using TaqMan assays, and the ABI Prism 7900 HT Sequence Detection System. Because few individuals carried the latter variants, genetic analyses were limited to 516G→T and 983T→C. Composite *CYP2B6* genotypes were assigned as follows: “extensive metabolizer” denoted no variant allele at either position 516 or 983; “intermediate metabolizer,” a single variant allele at either position 516 or 983; “slow metabolizer,” 2 variant alleles (i.e., either 516 TT, 983 CC, or 516 GT with 983 TC).¹⁸

Pharmacokinetic and statistical analyses

Sample size—It was estimated that a sample size of 28 volunteers would achieve 80% power to test whether or not co-administration of efavirenz resulted in a single-dose bedaquiline area under the curve (AUC) that differed from that observed with bedaquiline alone by $\geq 20\%$, assuming a bedaquiline coefficient of variance of 35% and a significance level of 0.05 using a two-sided paired-sample t-test. Sample size was increased to 35 to account for inefficiencies associated with using nonparametric tests and the possibility of unusable assay results after study closure.

Pharmacokinetic and statistical evaluation—Bedaquiline and efavirenz pharmacokinetic parameters, including AUC, maximum plasma concentration (C_{max}), half-life ($T_{1/2}$), and oral clearance (CL/F) were calculated using standard noncompartmental methods performed in SAS and confirmed using WinNonLin® software, version 6.1 (Pharsight, Cary, NC). Specifically, CL/F was estimated as $\text{dose}/\text{AUC}_{0-336h}$. Also, bedaquiline has triphasic elimination, so $T_{1/2}$ reported here represents average $T_{1/2}$ over the 336-hour pharmacokinetic sampling period; that is, $T_{1/2}$ was estimated using the best-fitting log-linear regression model in the drug elimination phase for each participant. Given the long terminal $T_{1/2}$ of bedaquiline, low residual concentrations prior to the intake of the second dose of bedaquiline were anticipated. Bedaquiline and M2 were non-zero at the time of the second single-dose administration, and corrections for residual concentrations in pharmacokinetic period 2 were performed prior to pharmacokinetic analysis by subtracting the estimated carryover concentrations from the observed concentrations in pharmacokinetic period 2. Estimated carryover concentrations were obtained by fitting a log-linear model to the concentrations observed during the terminal elimination phase of the first single-dose. Statistical analyses for the study objectives were based on nonparametric tests, and the p-values for these Wilcoxon signed-rank tests comparing pharmacokinetics of bedaquiline co-administered with efavirenz to bedaquiline alone are reported. Calculated geometric means of ratios (GMR) and 90% confidence interval were also used to compare pharmacokinetic

parameter estimates of bedaquiline alone and in the presence of steady-state efavirenz. M2 pharmacokinetic estimation and comparisons were performed using similar procedures. Efavirenz pharmacokinetic parameters were estimated using standard noncompartmental methods, and descriptive statistics of efavirenz pharmacokinetic parameters were summarized by *CYP2B6* genotype status.

RESULTS

Subjects

Thirty-seven subjects were enrolled and received the first dose of bedaquiline. The median age was 44 years (range 19–62), and 34 (92%) were male. The median weight and body mass index were 82.9 kg (range 57–119) and 26 (19–36), respectively. Twenty-six (70%) participants were white, non-Hispanic; 8 (22%) were black, non-Hispanic; 2 (5%) were Hispanic; and 1 (2%) was Asian. Of the 37, one was removed from the study for missing study visits, one withdrew for personal reasons (relocation), one was discontinued for study drug nonadherence, and one developed grade 3 serum transaminase elevations, prompting study drug discontinuation. Thirty-three participants were, thus, eligible for analysis of pharmacokinetic endpoints.

Effect of efavirenz on bedaquiline and M2 pharmacokinetics

Figure 2 shows the mean (SE) single-dose bedaquiline and M2 log-transformed plasma concentration-time curves for single doses of bedaquiline 400 mg taken alone (pharmacokinetic period 1, PK1)) or with steady-state efavirenz 600 mg daily. (pharmacokinetic period 2, PK2)). The median bedaquiline AUC_{0-336h} was 58,156 ng*h/mL for bedaquiline alone and 52,135 ng*h/mL for bedaquiline co-administered with efavirenz ($p < 0.001$) (Table 1). The $AUC_{0-336hPK2}:AUC_{0-336hPK1}$ GMR was 0.82 (90% CI 0.75–0.89). Oral clearance of bedaquiline was increased with concomitant efavirenz, while bedaquiline C_{max} was not significantly affected. The median M2 C_{max} was 42.4 ng/mL for bedaquiline alone and 83.29 ng/mL for bedaquiline co-administered with efavirenz ($p < 0.001$) (Table 1). The $C_{maxPK2}:C_{maxPK1}$ GMR was 1.89 (90% CI 1.65 to 2.15). The AUC_{0-336h} of M2, however, did not differ significantly between the two pharmacokinetic periods. Our analyses suggested a non-significant trend toward inverse correlations between efavirenz AUC_{0-24h} values and change from period 1 to period 2 in AUC_{0-336h} values for bedaquiline ($r = -0.34$, $p = 0.053$) and M2 ($r = -0.3$, $p = 0.089$, see Supplemental Figure S1).

Efavirenz pharmacokinetics

Median (IQR) AUC_{0-24h} for efavirenz was 56.87 $\mu g \cdot h/mL$ (42.27–74.99), C_{max} was 3.98 $\mu g/mL$ (3.32–5.49), and C_{min} was 1.58 $\mu g/mL$ (1.04–2.06). These values are similar to mean steady-state parameters reported among HIV-infected adults (58.09 $\mu g \cdot h/mL$, 4.07 $\mu g/mL$, and 1.77 $\mu g/mL$, respectively).²² Among the 33 study participants eligible for pharmacokinetic analysis, 3 (9%) had *CYP2B6* slow metabolizer genotypes (two with 516TT, one with 516GT/983TC), 12 (36%) intermediate metabolizer genotypes (ten with 516GT, two with 983TC), and 18 (55%) extensive metabolizer genotypes. Median efavirenz concentrations stratified by *CYP2B6* genotype are shown in Table 2 and Figure 3. Efavirenz C_{24h} values among *CYP2B6* extensive, intermediate, and slow metabolizers in the present study were similar to previously described steady-state C_{24h} values stratified by *CYP2B6* metabolizer genotype among HIV-infected adults.²³

Safety and tolerability of single-dose TMC with steady-state efavirenz

Grade 2 or higher clinical or laboratory adverse events are reported in supplemental Table S1. There were no serious adverse events and no clinical adverse events of grade 3 or higher. One subject developed grade 2 serum transaminase elevations 14 days after the first dose of bedaquiline that increased to grade 3 on the first day of efavirenz dosing, prompting discontinuation of study drug. Another developed grade 3 hypoglycemia while taking efavirenz, which resolved without specific intervention. Mean increase in QTcF (using Fredericia's correction) from baseline to 4–6 hours after the first and second bedaquiline doses was 12.3 milliseconds (95% CI 6.92–17.6) and 12.8 milliseconds (95% CI 7.49–18.1), respectively. One subject had a QTcF that was 450 milliseconds after the second bedaquiline dose, and another had a QTcF that was 452 after the first dose and 450 after the second dose (all were grade 1 toxicities), but all other post-dose QTcF were below the upper limit of normal (450 milliseconds by Fredericia). There were no statistically significant associations between bedaquiline or M2 C_{max} and changes in QTcF for either bedaquiline dose administration period.

DISCUSSION

Co-infection with HIV-1 and *M. tuberculosis* is common, and concurrent treatment is now recommended.^{24, 25} The widely prescribed ARV efavirenz can induce CYP3A isoforms, and the promising investigational agent for TB, bedaquiline, is a CYP3A substrate. The most important finding from the present study is that steady-state efavirenz reduced the AUC of bedaquiline by only a median of about 20%. While the C_{max} of the M2 metabolite was increased almost 90%, the AUC of M2 was unchanged. That efavirenz co-administration results in only a modest decrease in bedaquiline exposure is reassuring, given that drug-drug interactions can be problematic during treatment of TB/HIV co-infection and limit therapeutic options for HIV-infected patients with TB. Safety implications of higher peak concentrations of the M2 metabolite, however short-lived, are unclear.

The clinical consequences of diminished bedaquiline concentrations for patients receiving bedaquiline-containing multidrug therapy for the treatment of TB are not known, but the change associated with efavirenz co-administration is modest and unlikely to be clinically relevant. Pharmacodynamic targets for bedaquiline have not been well-established, but preclinical and clinical data do suggest dose-response relationships. In dose-ranging monotherapy studies in the mouse acute infection model, bedaquiline at 6.5 mg/kg delivered 5 times per week was bacteriostatic, and a dose increase from 12.5 mg/kg to 25 mg/kg yielded a one-log decline in lung colony forming units (CFU) after 4 weeks.^{7, 26} More recent dose-fractionation studies in the mouse acute infection model have shown a dose-response relationship between bedaquiline dose and lung CFU counts when doses from 8 to 64 mg/kg were tested, and the effects appeared to be concentration-dependent. (personal communication, Dr. Koen Andries, 8/31/2011). The optimal effect of bedaquiline in the mouse model was at plasma concentrations of approximately 0.3 mcg/mL, achieved with about 100 mg/kg per week.⁷ However, in mice, 80% of bedaquiline is converted to the M2 metabolite, whereas in humans the circulating M2:bedaquiline ratio is 1:4.

Given that M2 is 3- to 6-fold less active against *M. tuberculosis* than bedaquiline, pharmacokinetic/pharmacodynamic targets may differ in mice and humans. In a 7-day early bactericidal activity (EBA) study of bedaquiline monotherapy in humans, doses up to 200 mg daily showed no demonstrable activity, but 400 mg daily resulted in late declines in daily sputum colony counts.²⁷ When given in multidrug regimens for MDR-TB, a dose of 400 mg once daily for two weeks followed by 200 mg thrice-weekly achieved plasma concentrations above 600 ng/mL throughout the dosing interval, a target that may achieve therapeutic efficacy similar to 25 mg/kg in mice.¹⁴ No correlation between average

bedaquiline concentration and outcomes, however, was seen in this Phase II study, so target concentrations in humans remain uncertain.

Bedaquiline is a cationic amphiphilic drug, as defined by a hydrophobic ring structure plus a hydrophilic side chain with a charged cationic amine group. Cationic amphiphilic drugs can cause phospholipidosis, characterized by the accumulation of phospholipids in cells.²⁸ Phospholipidosis is thought to be an adaptive response rather than a manifestation of direct cellular toxicity, but phospholipidosis can have clinical consequences, including prolonged QT interval, myopathy, hepatotoxicity, nephrotoxicity, or pulmonary dysfunction.²⁹ These effects are generally reversible with drug discontinuation. There is no reliable biomarker predictive of drug-related phospholipidosis, and animal models do not appear to predict human responses well, posing regulatory challenges.³⁰ *In vitro*, M2 was a stronger inducer of phospholipidosis than amiodarone, and M2 induced phospholipidosis at lower concentrations than bedaquiline (1.2 μ M vs. 7.3 μ M, respectively).³¹ Concentrations of M2 in our study were far lower than those that produced phospholipidosis in *in vitro* models ($C_{\max}$ of 83.3 ng/mL=0.154 μ M), but these were not steady-state concentrations. In the current study, ECGs were performed 4–6 hours following each single dose of bedaquiline. In a post-hoc analysis in this small dataset, there was no correlation between change in QTcF from baseline and either AUC or $C_{\max}$ for bedaquiline or M2. Although QTc was slightly prolonged with both doses of bedaquiline, all but two subjects had ECGs with intervals within the normal range (<450 milliseconds).

Bedaquiline is primarily metabolized via oxidative N-demethylation to M2, and this biotransformation is largely catalyzed by CYP3A. M2 can be further N-demethylated to M3 or, alternatively, oxidized to M4. In this study, when efavirenz was co-administered with bedaquiline, M2 concentrations were initially increased resulting in a higher $C_{\max}$, but clearance of M2 also appeared to be enhanced, leading to similar overall M2 exposures, or AUC_{0-336h}. This could be explained by increased velocity and capacity of enzymatic transformation of bedaquiline to M2 in the setting of efavirenz coupled with induction of further biotransformation of M2 to a secondary metabolite. M3 or M4 concentration-time data would be needed to confirm this. If M2 is both formed and cleared more rapidly with concomitant efavirenz, steady-state M2 $C_{\max}$ is unlikely to be higher when bedaquiline is given with efavirenz than when bedaquiline is given alone. To test this assumption, nonlinear mixed effects modeling is underway to estimate steady-state M2 parameters using these single-dose data and taking into account triphasic bedaquiline elimination and M2 metabolite kinetics.

Efavirenz is a substrate of CYP2B6 and CYP3A and also induces these metabolizing enzymes, resulting in autoinduction of metabolism and diminished efavirenz concentrations with multiple dosing.³² The *CYP2B6* polymorphisms 516G→T and 983T→C predict decreased plasma clearance and increased steady-state efavirenz exposure.¹⁸ In the present study, as expected, plasma efavirenz exposure was strongly associated with *CYP2B6* metabolizer genotype. The pharmacokinetics of efavirenz should not be affected by bedaquiline. It is therefore reassuring that, within each *CYP2B6* genotype group, efavirenz pharmacokinetic parameters were similar to previously reported values.²² In drug-drug interaction studies that involve efavirenz it is important to determine *CYP2B6* metabolizer genotypes of study participants so as to more accurately interpret efavirenz pharmacokinetic parameters. In addition, results from participants with *CYP2B6* slow, intermediate, and extensive metabolizer genotypes suggest that our findings are generalizable regardless of *CYP2B6* genotype. This is important since *CYP2B6* slow metabolizer genotypes vary in frequency depending on geographic region of ancestry, and are most frequent among populations of African descent.³³ There is a correlation between efavirenz AUC and hepatic

CYP3A induction, but the dose or clinical exposure at which maximal induction is achieved is unknown.³⁴

There are several limitations of this study. Because bedaquiline was given as two single doses, the full safety and tolerability profile of bedaquiline with efavirenz could not be assessed. Although M2 is eliminated more rapidly when bedaquiline is given with efavirenz, it is unknown whether this represents increased metabolism of M2 to a secondary metabolite or another process because we did not measure other metabolites. Rifampin reduces bedaquiline concentrations by 50%.³⁵ Since the mechanism by which efavirenz induces CYP3A has not been fully elucidated,³⁶ it is unclear whether efavirenz would further diminish bedaquiline concentrations among patients who are also receiving concomitant rifampin. Finally, while we found no clear association between efavirenz concentrations and change in bedaquiline exposures, we studied relatively few individuals with *CYP2B6* slow metabolizer genotypes; trends seen in our analyses would need to be confirmed in a larger group of patients.

In conclusion, bedaquiline concentrations were only modestly reduced when bedaquiline was given together with efavirenz, a decrease that is unlikely to be clinically significant. Peak concentrations of the M2 metabolite were increased in this single-dose study, but once formed, M2 appears to be more rapidly cleared in the setting of efavirenz, and this will likely result in steady-state concentrations of M2 that do not significantly differ when bedaquiline is given with or without efavirenz. The present study indicates that efavirenz should not compromise the therapeutic efficacy of bedaquiline against TB. Further analyses will be needed to understand the implications, if any, of the effects of efavirenz on M2 metabolite pharmacokinetics.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Sources of support: This study was supported by the AIDS Clinical Trials Group sponsored by the National Institute of Allergy and Infectious Diseases and was supported by the following grants: U01 AI068636 and AI068634, U01 AI069497 (AG), U01 AI069465 (AG, CF, IW) AI0699450 (SS), U01 AI069439, R01 AI077505 (DWH), and K23AI080842 (KED). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. The ACTG Human DNA Repository is supported in part by grant UL1 RR024975. Tibotec Pharmaceuticals and Bristol-Myers Squibb provided study medications.

The study team thanks the individuals who volunteered for and participated in this study. We acknowledge the support of the analytical laboratory at University of California at San Francisco. In particular, we appreciate the contributions of study team members Laura Blair, Rob Camp, Ruth Ebiasah, Richard Hafner, Darlene Lu, Adam Manzella, and Susan Owens. We also thank Rachel Wiseman, Danielle Richardson, and Paul Leger in the Vanderbilt DNA Resources Core for *CYP2B6* genotyping.

We appreciate the efforts of the investigators and research staff at the following Adult ACTG units and Clinical Trials Sites:

Deborah Sutherland, RN, BSN, CCRP and Marcia Free, RN, BSN, CCRP- Vanderbilt Therapeutics Clinical Research Site #3652 NIH/AACTG Grant U01-AI06439, Vanderbilt CTSA grant UL1 RR024975 from NCRR/NIH.

Miriam Chicurel, BS, BSN and Charles W Tedder, BA- UNC AIDS Clinical Trials Unit Site 3201, ACTG Grant 5-U01 AI069423, CTSA Grant UL1 RR025747 CTSA.

Susan L. Koletar, MD and Heather Harber, RN- The Ohio State University, 2301 ACTG Grant U01 AI069474, Clinical Research Center, Grant UL1-RR025755 from the National Center of Research Resources of the NIH.

Annie Luetkemeyer, MD and Jay Dwyer, RN- UCSF AIDS CRS (Site 801) Grant # 5U01 AI069502.

Judith Hackman, RN and Andrea Weiss, RPh- Johns Hopkins University CTU (Site 201) CTU Grant AI69465; GCRC Grant U54-RR023561.

References

1. World Health Organization. Global tuberculosis control. 2010. WHO/HTM/TB/2010.7. Available at: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf
2. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med*. 2010; 362:697–706. [PubMed: 20181971]
3. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis. *N Engl J Med*. 2011; 365:1492–1501. [PubMed: 22010915]
4. Blanc F, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med*. 2011; 365:1471–1481. [PubMed: 22010913]
5. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med*. 2011; 365:1482–1491. [PubMed: 22010914]
6. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. *J Infect Dis*. 2007; 196 (Suppl 1):S63–75. [PubMed: 17624828]
7. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science*. 2005; 307:223–7. [PubMed: 15591164]
8. Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. *Antimicrob Agents Chemother*. 2006; 50:3543–7. [PubMed: 16954317]
9. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. *Nat Chem Biol*. 2007; 3:323–4. [PubMed: 17496888]
10. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. *Antimicrob Agents Chemother*. 2007; 51:1011–5. [PubMed: 17178794]
11. Veziris N, Ibrahim M, Lounis N, et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. *PLoS One*. 2011; 6:e17556. [PubMed: 21408613]
12. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin, and pyrazinamide against *Mycobacterium tuberculosis* infection in guinea pigs. *Antimicrob Agents Chemother*. 2011; 55:124–31. [PubMed: 20937788]
13. Zhang T, Li SY, Williams KN, et al. Short-course Chemotherapy with TMC-207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection. *Am J Respir Crit Care Med*. 2011
14. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med*. 2009; 360:2397–405. [PubMed: 19494215]
15. McNeeley, D.; Diacon, AH.; Pym, A., et al. TMC-207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial; November 11–15; Berlin.
16. Matteelli A, Carvalho AC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. *Future Microbiol*. 2010; 5:849–58. [PubMed: 20521931]
17. Tibotec. TMC207-TIDP13. 6. December. 2010 Investigator's Brochure.
18. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. *J Infect Dis*. 2009; 199:872–80. [PubMed: 19239339]
19. Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. *J Infect Dis*. 2009; 200:955–64. [PubMed: 19659438]
20. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0. Available at:

[http://rsc.tech-res.com/Document/safetyandpharmacovigilance/
Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf](http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf)

21. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. *Clin Infect Dis*. 2008; 47:421–4. [PubMed: 18558886]
22. Sustiva [package insert]. Princeton, NJ: BMS; 2003.
23. Liu, H.; Ribaud, HJ.; Acosta, EP., et al. Pharmacogenetics of low plasma efavirenz (EFV) concentrations in AIDS Clinical Trials Group (ACTG) studies: Analysis NWCS 301. Presented at 12th International Workshop on Clinical Pharmacology of HIV Therapy; Miami, FL. April. 2011;
24. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents -November 2009 [electronic version]. Available at: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
25. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [January 10, 2011 Available at: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>
26. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. *Antimicrob Agents Chemother*. 2010; 54:4540–4. [PubMed: 20713662]
27. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. *Antimicrob Agents Chemother*. 2008; 52:2831–5. [PubMed: 18505852]
28. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. *Expert Opin Drug Saf*. 2006; 5:567–83. [PubMed: 16774494]
29. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. *Toxicol Pathol*. 1997; 25:53–60. [PubMed: 9061852]
30. ACPS meeting. United States Federal Drug Administration; April 14, 2010 The regulatory challenges of drug-induced phospholipidosis. Available at: <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/advisorycommitteeforpharmaceuticalscienceandclinicalpharmacology/ucm210798.pdf>
31. Mesens, N.; Verbeeck, J.; Rouan, MC., et al. Elucidating the role of M2 in the preclinical safety profile of TMC207. Abstract PS-71291-11. 38th Union World Conference on Lung Health; 8–12 November 2007; Cape Town, South Africa.
32. Zhu M, Kaul S, Nandy P, et al. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. *Antimicrob Agents Chemother*. 2009; 53:2346–53. [PubMed: 19223624]
33. dbSNP Short Genetic Variations. <http://www.ncbi.nlm.nih.gov/projects/SNP>
34. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. *Clin Pharmacol Ther*. 2002; 72:1–9. [PubMed: 12151999]
35. Lounis N, Gevers T, Van Den Berg J, et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. *Antimicrob Agents Chemother*. 2008; 52:3568–72. [PubMed: 18644960]
36. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. *J Pharmacol Exp Ther*. 2007; 320:72–80. [PubMed: 17041008]

Figure 1.
Schematic of the dosing regimen and pharmacokinetic sample collection.

Figure 2. Mean bedaquiline (A) and M2 (B) plasma concentration versus time curve after single dose of bedaquiline dosed at 400 mg alone (solid line) and single dose bedaquiline given together with steady state efavirenz (dashed line). Values shown represent means with standard error.

Figure 3. Mean (SE) efavirenz plasma concentrations versus time curves, stratified by *CYP2B6* metabolizer genotype.

Table 1

Pharmacokinetic parameters of bedaquiline and its M2 metabolite when bedaquiline is administered alone (single oral dose of 400 mg) or co-administered with steady-state efavirenz (efavirenz at a dose of 600 mg by mouth daily).

Bedaquiline					
Pharmacokinetic parameter	Alone*	With efavirenz*	GMR**	90% CI	p-value[†]
AUC ₀₋₃₃₆ (ng* h/mL)	58155(42222, 78249)	52135 (39868, 62528)	0.82	(0.75–0.89)	<0.001
C _{max} (ng/mL)	3390 (2420, 4290)	3708 (2716, 4529)	1.00	(0.88, 1.13)	0.88
T _{max} (h)	5.0 (5.0, 6.0)	5.0 (5.0, 5.0)	0.95	(0.85, 1.07)	0.25
T _{1/2} (h)	51.1 (48.7, 55.3)	47.5 (43.5, 53.0)	0.92	(0.88, 0.97)	0.006
CL/F (l/h)	6.88 (5.11, 9.47)	7.67 (6.40, 10.03)	1.22	(1.12, 1.33)	<0.001
M2 metabolite					
AUC ₀₋₃₃₆ (ng* h/mL)	7432 (6189, 9753)	8542 (6274, 10589)	1.07	(0.97, 1.19)	0.295
C _{max} (ng/mL)	42.4 (34.9, 50.3)	83.3 (56.2, 107.9)	1.89	(1.66, 2.15)	<0.001
T _{max} (h)	12 (8.0, 12)	8.0 (8.0, 12)	0.73	(0.55, 0.97)	0.080
T _{1/2} (h)	231.3 (207.6, 321.1)	100.44 (87.8, 142.8)	0.50	(0.38, 0.53)	<0.001
CL/F (l/h)	53.9 (41.0, 64.6)	46.8 (37.8, 63.8)	0.93	(0.84, 1.03)	0.295

* Values are medians (IQR).

** Geometric mean of ratios (GMR) of pharmacokinetics of bedaquiline co-administered with efavirenz to bedaquiline alone.

[†] p-value of Wilcoxon signed-rank test comparing pharmacokinetics of bedaquiline co-administered with efavirenz to bedaquiline alone.

Table 2

Summary of efavirenz pharmacokinetic parameters for A5267 study participants, by *CYP2B6* metabolizer status.

PK parameter	Metabolizer status	N	Median (IQR)
AUC _{0-24h} (µg/mL)	Extensive	18	46.50 (32.78, 57.99)
	Intermediate	12	65.31 (49.48, 84.36)
	Slow	3	99.50 (74.99, 143.3)
C ₂₄ (µg/mL)	Extensive	18	1.33 (0.89, 1.72)
	Intermediate	12	3.06 (1.47, 2.46)
	Slow	3	3.71 (2.62, 4.93)
C _{max} (µg/mL)	Extensive	18	3.84 (2.36, 40.2)
	Intermediate	12	4.66 (3.59, 5.81)
	Slow	3	5.94 (4.88, 9.95)
CL/F (L/hour)	Extensive	18	12.9 (10.3, 18.3)
	Intermediate	12	9.19 (7.11, 12.2)
	Slow	3	6.03 (4.19, 8.00)
T _{1/2} (hour)	Extensive	18	15.0 (13.2, 19.7)
	Intermediate	12	16.6 (14.5, 23.9)
	Slow	3	25.5 (25.3, 32.8)